Form 4: Eli Lilly Director Defers Compensation into Stock Units

Sentiment:

Insider Transaction Report


Eli Lilly & Co. Director Ralph Alvarez acquired 11.062 shares of common stock by deferring cash compensation into stock units under the company's deferral plan.

Summary

  • Ralph Alvarez, a Director at Eli Lilly & Co. (LLY), acquired 11.062 shares of common stock on December 15, 2025.
  • The acquisition was made by deferring cash compensation, valued at $1,062.19, into stock units under the Lilly Directors' Deferral Plan.
  • These stock units will be settled in shares of common stock following Mr. Alvarez's separation from service.
  • Following this transaction, Mr. Alvarez directly beneficially owns 55,467.718 shares and indirectly owns 758 shares through a Trust.
  • The transaction was made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 6

Explanation: The filing indicates a routine insider transaction related to director compensation, which is generally neutral to slightly positive as it aligns director interests with shareholders. No significant new information to alter sentiment.

Positives

  • A Director is increasing their beneficial ownership in the company, aligning their interests with shareholders.
  • The deferral of cash compensation into stock units demonstrates a commitment to long-term investment in the company's equity.

Future Outlook

The acquired stock units will be settled in shares of common stock following the reporting person's separation from service.

Management Comments

  • Ralph Alvarez elected to defer cash compensation into stock units under the Lilly Directors' Deferral Plan, with settlement in common stock upon his separation from service.

Industry Context

The deferral of director compensation into equity is a common practice across industries, designed to align the interests of board members with those of long-term shareholders.

Corporate Governance

Change TypeDescriptionEffective DateImpact Assessment
Plan ReferenceShares acquired were deferred as stock units under the Lilly Directors' Deferral Plan, indicating an existing compensation and governance structure designed to align director interests with shareholders.N/AReinforces existing director compensation and alignment mechanisms, promoting long-term shareholder value.

Stakeholder Impact

  • Shareholders: Increased alignment of director's financial interests with long-term shareholder value through equity ownership.
  • Employees: No direct impact mentioned.

Next Steps

  • Settlement of the acquired stock units into shares of common stock upon Ralph Alvarez's separation from service.

Key Dates

DateDescription
12/15/2025Date of transaction where Ralph Alvarez acquired common stock units.
12/16/2025Date the Form 4 was signed.

Recommendation

hold

This Form 4 reports a routine director compensation deferral into stock units, which is a standard practice and does not provide new information to alter an investment recommendation. It indicates continued alignment of director interests with shareholders, but does not fundamentally change the investment thesis for Eli Lilly & Co.

Keywords

Eli Lilly, LLY, Form 4, Insider Transaction, Director Compensation, Stock Units, Beneficial Ownership, Rule 10b5-1

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.